The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.00
Bid: 45.10
Ask: 48.00
Change: 0.50 (1.10%)
Spread: 2.90 (6.43%)
Open: 46.00
High: 46.00
Low: 46.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

25 May 2017 07:00

RNS Number : 1690G
Benchmark Holdings PLC
25 May 2017

Benchmark Holdings PLC

25 May 2017

Benchmark Holdings plc("Benchmark", the "Company" or the "Group")

Trading Update and Notice of Results

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces that Group performance for the six months to 31 March 2017 was broadly in line with the Board's expectations.

Highlights of the first half year include:

Benchmark signed a joint venture agreement with SalMar ASA, through which it will provide genetics, health and knowledge services to the world's third largest salmon producer. This is an important acknowledgement of Benchmark's technology, and exemplifies its strategy to provide a suite of technology solutions to the aquaculture industry.

Construction of the Group's new salmon egg production facility in Norway continued on schedule. This important development will underpin Benchmark Breeding and Genetics' market leading position in the sector.

Good progress was made in Advanced Animal Nutrition towards the goal of delivering 100% live replacement for feeding juvenile shrimp, a key to unlocking future growth potential for the industry.

As anticipated, the Animal Health division saw significantly lower demand for Salmosan in Norway due to an industry focus on new solutions to the significant sea lice challenge.

Good progress was made towards the commercial field trials launch of a ground-breaking sea lice treatment. Significant revenues from this product are anticipated in H2 and beyond, which are projected to support achievement of the Board's expectations for FY 2017 following the challenging first half for Salmosan.

The new state-of-the-art vaccine manufacturing facility in Braintree is being commissioned and first commercial batches are expected in H2.

In the shrimp sector, disease challenge coupled with low market prices resulted in delayed sector investment and lower growth rates in the first half year. The Group has proceeded cautiously with new investments, whilst continuing to progress core infrastructure projects which support long term growth.

The Group is seeking to grow sales and market share in developing markets, including China, for its Breeding and Genetics and Advanced Animal Nutrition Divisions, and is progressing towards establishing strategic relationships in those regions. Further progress has been made with the development of the Group-wide customer account management programme, which will promote the full benefit of Benchmark's integrated technology solutions in aquaculture.

The long term drivers of growth in the Company's sectors, which include the growing global demand for aquaculture products and an ever increasing pressure to limit the use of antibiotics in the food chain, remain strong, with increasing momentum and interest in the aquaculture market. The Company continues to focus on delivery of its strategy to deploy leading technologies drawn from across the Group, through established distribution channels, into long-term growth markets.

Benchmark expects to announce its interim results for the six months to 31 March 2017 during the week commencing 26 June 2017.

Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said:

"The agreement with SalMar is an example of the value we can deliver to our customers by aggregating leading technologies to provide integrated solutions to the issues faced by the food production industry. There are a number of technologies in the later stages of development that we are particularly excited about, and we look forward to delivering these, through our distribution networks, including into the significant Asian and Latin American shrimp and tilapia markets."

-Ends-

For further information, please contact:

Benchmark Holdings plc

聽Tel: 020 7920 3150

聽Malcolm Pye, CEO

聽Roland Bonney, COO

聽Rachel Aninakwah, Communications

Numis

聽Tel: 020 7260 1000

聽Michael Meade / Freddie Barnfield (NOMAD)

聽James Black (Corporate Broking)

Tavistock

聽Tel: 020 7920 3150

聽Niall Walsh / Simon Hudson

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 28 February 2017, Benchmark employed 900 people.

For further information on Benchmark please visit www.benchmarkplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFVDEVISFID
Date   Source Headline
25th Apr 20247:00 amRNSForm 8.3 - BENCHMARK HOLDINGS PLC
23rd Apr 202410:44 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
23rd Apr 20247:00 amRNSRule 2.9 Announcement
22nd Apr 202410:42 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
19th Apr 20249:23 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
18th Apr 202410:37 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
17th Apr 20244:13 pmRNSFORM 8.3 - BENCHMARK HOLDINGS PLC
17th Apr 202410:27 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
16th Apr 20249:54 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
11th Apr 202410:51 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
8th Apr 202411:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
5th Apr 202410:38 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
5th Apr 20249:23 amRNSForm 8.3 - Benchmark Holdings plc
28th Mar 202412:00 pmRNSTotal Voting Rights
22nd Mar 202411:51 amRNSForm 8.3 - Benchmark Holdings plc
22nd Mar 202410:52 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
22nd Mar 202410:33 amRNSBENCHMARK Holdings PLC
21st Mar 20249:58 amRNSForm 8.3 - Benchmark Holdings plc
21st Mar 20247:00 amRNSBlock Listing Six Monthly Return
20th Mar 202411:28 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
19th Mar 202410:01 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
15th Mar 202411:13 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
7th Mar 202411:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
7th Mar 20247:00 amRNSRule 2.9 Announcement
6th Mar 202410:36 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
5th Mar 202411:10 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
4th Mar 20243:13 pmGNWForm 8.3 - [BENCHMARK HOLDINGS PLC - 01 03 2024] - (CGAML)
4th Mar 202411:22 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
29th Feb 202411:19 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
29th Feb 20247:00 amRNSTotal Voting Rights
27th Feb 202411:24 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
26th Feb 202411:06 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
23rd Feb 202411:23 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
22nd Feb 20243:15 pmRNSForm 8.3 - BENCHMARK HOLDINGS PLC
21st Feb 202411:24 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
20th Feb 202411:40 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
19th Feb 202410:59 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
16th Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
15th Feb 20247:00 amRNSQ1 Results
14th Feb 202411:37 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
8th Feb 20244:00 pmRNSResult of AGM
6th Feb 20244:08 pmRNSForm 8.3 - Benchmark Holdings PLC
6th Feb 20247:36 amRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 20245:30 pmRNSRule 2.9 Announcement
5th Feb 20242:50 pmRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 202410:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
1st Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
1st Feb 202410:16 amRNSForm 8.3 - Benchmark Holdings plc
31st Jan 20242:03 pmRNSForm 8.3 - Benchmark Holdings
31st Jan 20247:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.